

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/204227 A1

(51) International Patent Classification:

A61P 29/00 (2006.01) C07D 405/12 (2006.01)
C07D 209/14 (2006.01) C07D 409/12 (2006.01)
C07D 231/56 (2006.01) C07D 413/12 (2006.01)
C07D 401/12 (2006.01) C07D 417/12 (2006.01)
C07D 403/12 (2006.01) C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2022/021461

(22) International Filing Date:

23 March 2022 (23.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/164,780 23 March 2021 (23.03.2021) US
63/219,538 08 July 2021 (08.07.2021) US

(71) Applicants: **BIOAGE LABS, INC.** [US/US]; 1445A S 50th Street, Richmond, CA 94804 (US). **HITGEN, INC.** [CN/CN]; Building 6, No. 8, Huigu 1st East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan, 610200 (CN).

(72) Inventors: **HARTMAN, George**; 1529 Tennis Circle, Lansdale, PA 19446 (US). **HE, Xu**; c/o Hitgen, Inc., Building 6, No. 8, Huigu 1st East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200 (CN). **DU, Jia**; c/o Hitgen, Inc., Building 6, No. 8, Huigu 1st East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200 (CN). **ZHANG, Li-fang**; c/o Hitgen, Inc., Building 6, No. 8, Huigu 1st East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200 (CN). **HUMPHRIES, Paul**; 2087 Sharon Road, Menlo Park, CA 94025 (US). **WILHELMSEN, Kevin Edward, Leif**; 1076 Masonic Ave., Albany, CA 94706 (US).

(74) Agent: **TRINQUE, Brian, C.** et al.; Lathrop GPM LLP, 28 State Street, 7th Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

WO 2022/204227 A1

(54) Title: INHIBITORS OF NLRP3 INFLAMMASOME

(57) Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.